Brightcove Launches Industry-Leading Virtual Event Experiences Solution; Empowering Companies to Quickly and Easily Connect with Audiences Online
25.6.2020 16:10:00 EEST | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the world’s leading video technology platform, today announced Brightcove Virtual Event Experiences, a solution that allows organizations to deliver high-quality virtual events featuring bold, interactive experiences. Responding to a crucial market need, Brightcove Virtual Event Experiences enables organizations to host events with market-leading video technology to engage with audiences securely and reliably around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005507/en/
The adoption of video communications in enterprise organizations is growing at a rapid pace. According to the recent Brightcove Global Video Index, in the first quarter of 2020, video views among enterprise companies increased by 91% year over year, with preliminary year-over-year data from April and May showing viewing increases of nearly 80% and 54%, respectively. Along with this adoption, many in-person events and meetings are moving to online video. With no timetable for the return of large-scale, in-person conferences and events, marketing and event professionals are looking for an in-person alternative, and they are turning to Brightcove for guidance. Recently, Brightcove technology has helped power critical B2B, B2C, and arts/entertainment events, helping organizations scale quickly, easily, and securely while reaching new audiences across the globe, including:
- ServiceNow Knowledge 2020
- DocuSign MomentumLive
- Talkdesk® Opentalk 2020 Virtual
- NAB Show Express with over 40,000 industry professionals accessing the event since its launch
- The Dropkick Murphys’ Streaming Outta Fenway concert joined by Bruce Springsteen with over 9 million live and on-demand views to date, raising over $700,000 for charity
- The Metropolitan Opera's At Home Gala, with more than 40 artists participating from around the world, was watched by more than 750,000 people
The need to engage with customers and prospects is as critical as ever, and organizations expect to deliver innovative and measurable experiences for their audiences in order to maintain communication and engagement. The Brightcove Virtual Events Experience solution empowers companies to take immediate action to ensure that their essential in-person events can continue virtually.
Features include:
- Branding and User Experience: Control the viewer’s experience and surrounding content by hosting on Brightcove.
- Increased Value for Sponsors: Demonstrate value to sponsors and exhibitors by offering integrated ads, complete with measurable and tangible analytics.
- Quality and Global Scale: Enable streaming video to global audiences in a secure environment.
- Security: Configure a variety of security options beyond password protection and geo-blocking, including SSO and integration with user management solutions.
- Expertise and support: Engage with Brightcove’s customer experience team and support organization to meet business objectives.
“Like most B2B companies, we had to quickly pivot from an in-person event to a virtual customer conference when COVID-19 hit. Our strategy was to embrace the remote reality but also to create an experience that felt like a performance and developed a sense of community,“ said Kathie Johnson, Chief Marketing Officer, Talkdesk. “To do this, we selected Brightcove as the platform and leveraged its integration partner Pigeonhole for the live polling and social interaction. One analyst who compared B2B customer conferences stated Opentalk 2020 virtual ‘struck the best balance of event duration, content, and engagement.’ The development process with Brightcove was seamless and the response to our program has been extremely positive.”
“The pandemic is video’s evolutionary moment, and as a result, video is now at the forefront of how we communicate with others, how we conduct business, and is enabling us to stay connected even when physically apart,” said Sara Larsen, Chief Marketing Officer, Brightcove. “Events are a place for information sharing, learning, business building, and networking. Now, more than ever, we need events to flourish and connect us in a virtual video experience. Brightcove Virtual Events Experiences allows organizations to deliver exceptional virtual events quickly and securely, without sacrificing the attendee experience. With this solution, we’re not only helping our customers adapt to the changing landscape but also allowing them to stay connected with their audiences with an engaging, innovative video-driven digital experience.”
For more information on Brightcove Virtual Event Experiences, visit: https://www.brightcove.com/en/solutions/virtual-event
About Brightcove Inc. (NASDAQ: BCOV)
We are the people behind the world’s leading video technology platform. With our award-winning technology and services, we help organizations in more than 70 countries meet business challenges and create strategic opportunities by inspiring, entertaining, and engaging their audiences through video.
Since Brightcove was established in 2004, we have consistently pushed boundaries to create a platform for people who are serious about video: one that is robust, scalable, and intuitive. Benefiting from a global infrastructure, unrivalled customer support, an extensive partner ecosystem, and relentless investment in R&D, Brightcove video sets the standard for professional grade video management, distribution, and monetization. To learn more, visit www.brightcove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005507/en/
Contact information
Press Contact
Meredith Duhaime
Senior Public Relations Manager
Brightcove | 603-785-8518
mduhaime@brightcove.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
